https://www.windhamcap.com https://www.windhamcap.com/about https://www.windhamcap.com/portfolio https://www.windhamcap.com/team https://www.windhamcap.com/contact https://www.windhamcap.com/news https://www.windhamcap.com/newsletter https://www.windhamcap.com/team/adam-fine https://www.windhamcap.com/team/alistair-erskine https://www.windhamcap.com/team/allan-bufferd https://www.windhamcap.com/team/bill-crouse https://www.windhamcap.com/team/david-kereiakes https://www.windhamcap.com/team/deneen-vojta https://www.windhamcap.com/team/jason-helgerson https://www.windhamcap.com/team/jeffrey-sachs https://www.windhamcap.com/team/joe-proto https://www.windhamcap.com/team/lorne-taichman https://www.windhamcap.com/team/roger-fine https://www.windhamcap.com/team/ruth-segall https://www.windhamcap.com/team/sara-vaezy https://www.windhamcap.com/team/sterling-snead https://www.windhamcap.com/news/200th-treatment-milestone-for-airflow-3-copd-trial https://www.windhamcap.com/news/adam-fine-founder-managing-partner-at-windham-venture-partners-on-beckers-healthcare-podcast https://www.windhamcap.com/news/allegheny-health-network-explores-use-of-promising-new-blood-based-test-to-enhance-lung-cancer-detection https://www.windhamcap.com/news/alto-neuroscience-announces-35-million-series-b-financing https://www.windhamcap.com/news/alto-neuroscience-announces-60-million-in-additional-financing https://www.windhamcap.com/news/alto-neuroscience-announces-positive-data-from-phase-1-study-evaluating-brain-effects-of-novel-drug-combinations https://www.windhamcap.com/news/alto-neuroscience-announces-positive-phase-1-results-for-alto-101-a-novel-pde4-inhibitor-in-development-for-schizophrenia https://www.windhamcap.com/news/alto-neuroscience-announces-positive-results-for-alto-100-in-phase-2-study-supporting-advancement-of-first-in-class-mechanism-for-treating-depression https://www.windhamcap.com/news/alto-neuroscience-announces-positive-results-from-phase-2-study-of-alto-100-in-post-traumatic-stress-disorder https://www.windhamcap.com/news/alto-neuroscience-announces-positive-results-from-phase-2-study-of-alto-300-in-major-depressive-disorder https://www.windhamcap.com/news/alto-neuroscience-closes-45-million-in-oversubscribed-series-c-financing https://www.windhamcap.com/news/alto-neuroscience-emerges-with-largest-clinical-stage-precision-psychiatry-pipeline-and-40-million-in-financing https://www.windhamcap.com/news/alto-neuroscience-presents-new-data-leveraging-eeg-and-machine-learning-to-predict-individual-response-to-antidepressants-at-the-61st-annual-meeting-of-the-american-college-of-neuropsychopharmacology https://www.windhamcap.com/news/alto-neuroscience-receives-funding-award-from-wellcome-trust-to-accelerate-development-of-alto-100-in-bipolar-depression-leveraging-precision-psychiatry-approach https://www.windhamcap.com/news/build-a-company-to-be-bought-not-sold-match-the-asset-to-the-capital-and-other-advice-from-vc-experts https://www.windhamcap.com/news/cerebral-and-alto-neuroscience-enter-into-strategic-collaboration-to-launch-first-ever-decentralized-study-in-precision-psychiatry https://www.windhamcap.com/news/chromacode-announces-partnership-with-medgenome-to-bring-hdpcr-based-diagnostics-to-india-and-the-middle-east https://www.windhamcap.com/news/chromacode-announces-strategic-investment-to-advance-development-and-application-of-hdpcr-platform-technology-for-use-in-oncology-genomics https://www.windhamcap.com/news/chromacode-lung-cancer-assay-shows-advantages-in-new-data-at-amp-as-company-eyes-next-applications https://www.windhamcap.com/news/chromacode-selected-as-a-winner-of-6m-xprize-rapid-covid-testing-competition https://www.windhamcap.com/news/city-of-hope-and-delfi-diagnostics-announce-collaboration-to-improve-lung-cancer-screening-rates-in-underserved-areas-of-los-angeles https://www.windhamcap.com/news/clever-care-announces-series-c-fundraising-adds-new-board-member https://www.windhamcap.com/news/clever-care-health-plan-raises-over-71-million-in-series-b-funding-to-accelerate-growth-of-its-medicare-advantage-hmo-plan https://www.windhamcap.com/news/controlrad-r-announces-fda-clearance-for-controlrad-select https://www.windhamcap.com/news/cvrx-added-to-russell-2000-r-and-3000-r-indexes https://www.windhamcap.com/news/cvrx-announces-new-real-world-evidence-demonstrating-significant-reductions-in-healthcare-utilization-with-barostim https://www.windhamcap.com/news/cvrx-inc-announces-upsized-pricing-of-initial-public-offering https://www.windhamcap.com/news/cvrx-r-receives-mr-conditional-labeling-approval-for-its-barostim-tm-heart-failure-system https://www.windhamcap.com/news/cvrx-receives-fda-approval-for-expanded-labeling-of-barostim https://www.windhamcap.com/news/david-kereiakes-managing-partner-at-windham-venture-partners https://www.windhamcap.com/news/delfi-diagnostics-announces-225-million-series-b-financing-to-develop-globally-accessible-portfolio-of-liquid-biopsy-tests https://www.windhamcap.com/news/delfi-diagnostics-announces-availability-of-new-fragmentome-based-cancer-treatment-monitoring-assay https://www.windhamcap.com/news/delfi-diagnostics-announces-equity-investment-from-the-merck-global-health-innovation-fund-to-accelerate-delfis-cancer-screening-ai-fragmentomics-platform https://www.windhamcap.com/news/delfi-diagnostics-appoints-susan-tousi-as-new-chief-executive-officer https://www.windhamcap.com/news/delfi-diagnostics-begins-enrollment-for-prospective-lung-cancer-screening-trial-ahead-of-planned-commercial-test https://www.windhamcap.com/news/delfi-diagnostics-initiates-15-000-patient-prospective-lung-cancer-screening-trial https://www.windhamcap.com/news/delfi-diagnostics-launches-firstlook-lung-an-accessible-accurate-new-way-to-enhance-lung-cancer-screening-through-a-routine-blood-test https://www.windhamcap.com/news/delfi-diagnostics-presents-additional-promising-proof-of-concept-data-on-its-monitoring-program-at-aacr-2023 https://www.windhamcap.com/news/delfi-diagnostics-selected-as-the-liquid-biopsy-partner-for-4-in-the-lung-run-a-large-scale-european-lung-cancer-screening-study https://www.windhamcap.com/news/delfi-diagnostics-selects-lahey-hospital-medical-center-to-administer-new-lung-cancer-screening-test https://www.windhamcap.com/news/delfi-diagnostics-working-with-incendia-therapeutics-to-employ-advanced-treatment-monitoring-test-in-a-phase-1-clinical-trial https://www.windhamcap.com/news/doug-schenkel-joins-delfi-diagnostics-as-chief-financial-officer https://www.windhamcap.com/news/experts-in-motion-the-state-of-medtech-funding https://www.windhamcap.com/news/fda-approves-novocures-optune-lua-r-for-the-treatment-of-metastatic-non-small-cell-lung-cancer https://www.windhamcap.com/news/femtech-leader-willow-r-adds-diverse-set-of-investors-in-extended-series-c-round https://www.windhamcap.com/news/fore-biotherapeutics-announces-75m-in-series-d-financing-and-ceo-transition https://www.windhamcap.com/news/fore-biotherapeutics-announces-oral-presentation-at-sno-2023-reporting-updated-phase-1-2a-results-for-plixorafenib-in-braf-v600-advanced-solid-tumors-including-novel-data-for-patients-with-braf-v600-primary-cns-tumors https://www.windhamcap.com/news/founder-friendly-investors-2024-introducing-the-capital-providers-with-a-track-record-of-supporting-founders https://www.windhamcap.com/news/generative-ai-in-your-desk-drawer-back-office-applications-in-health-care https://www.windhamcap.com/news/generative-ai-in-your-desk-drawer-how-to-get-there https://www.windhamcap.com/news/generative-ai-in-your-desk-drawer-llms-for-everyone https://www.windhamcap.com/news/growing-medication-management-optimization-company-cureatr-names-new-executive-leadership https://www.windhamcap.com/news/how-tailormed-is-removing-financial-barriers-to-healthcare https://www.windhamcap.com/news/indigenous-pact-and-delfi-diagnostics-join-forces-to-enhance-lung-cancer-screening-in-tribal-communities https://www.windhamcap.com/news/labcorp-strengthens-oncology-leadership-position-with-the-addition-of-personal-genome-diagnostics-a-provider-of-comprehensive-liquid-biopsy-and-tissue-based-genomic-products-and-services https://www.windhamcap.com/news/neuspera-medical-announces-close-of-a-65m-series-c-equity-financing https://www.windhamcap.com/news/neuspera-medical-announces-landmark-six-month-clinical-trial-results-for-the-first-battery-free-percutaneous-sacral-neuromodulation-psnm-system-for-urgency-urinary-incontinence-management https://www.windhamcap.com/news/neuspera-medical-inc-announces-milestone-completion-of-100th-implant-in-its-sans-uui-phase-ii-clinical-trial https://www.windhamcap.com/news/neuspera-medical-r-announces-fda-clearance-of-its-system-for-peripheral-nerve-stimulation https://www.windhamcap.com/news/neuspera-medical-r-announces-second-phase-of-sans-uui-ide-clinical-trial-with-the-nuvella-tm-system https://www.windhamcap.com/news/neuspera-medical-raises-23-million-in-series-d-financing https://www.windhamcap.com/news/neuspera-medical-receives-fda-approval-for-first-integrated-sacral-neuromodulation-isnm-system-for-urinary-urge-incontinence https://www.windhamcap.com/news/novel-approaches-are-essential-for-enabling-patient-first-outcomes-in-value-based-care-models https://www.windhamcap.com/news/novocure-announces-positive-topline-results-from-phase-3-panova-3-clinical-trial-of-tumor-treating-fields-ttfields-therapy-for-pancreatic-cancer https://www.windhamcap.com/news/nuvaira-announces-airflow-3-copd-pivotal-trial-milestone https://www.windhamcap.com/news/osf-healthcare-and-delfi-diagnostics-announce-collaboration-to-improve-lung-cancer-screening-rates https://www.windhamcap.com/news/painteq-secures-majority-growth-recapitalization-co-led-by-signet-healthcare-partners-windham-capital-partners https://www.windhamcap.com/news/personal-genome-diagnostics-enters-collaborative-partnership-with-clinical-molecular-diagnostics-laboratory-of-major-university-health-system https://www.windhamcap.com/news/phase-2-data-demonstrate-potential-of-vergent-biosciences-tumor-targeted-fluorescent-imaging-agent-to-improve-success-of-lung-cancer-surgeries https://www.windhamcap.com/news/positive-liver-cancer-detection-data-published-in-cancer-discovery-shows-further-promise-of-delfis-ai-liquid-biopsy-platform https://www.windhamcap.com/news/redefining-relief-how-painteq-is-transforming-lives-one-procedure-at-a-time https://www.windhamcap.com/news/revelle-aesthetics-unveils-new-minimally-invasive-procedure-for-cellulite-reduction https://www.windhamcap.com/news/subjectwell-acquires-patientcentra https://www.windhamcap.com/news/subjectwell-raises-35-million-to-expand-patient-access-to-new-treatment-options https://www.windhamcap.com/news/tailormed-secures-40-million-to-expand-the-largest-affordability-network-into-an-end-to-end-platform-transforming-patient-access-to-care-nationwide https://www.windhamcap.com/news/the-dye-that-binds-advances-in-tumor-visualization-now-help-surgeons-see-cancer-in-real-time https://www.windhamcap.com/news/upward-health-announces-contract-with-clover-health-to-serve-patients-in-four-states-under-new-direct-contracting-initiative https://www.windhamcap.com/news/upward-health-announces-growth-equity-financing-led-by-heritage-group https://www.windhamcap.com/news/upward-health-awarded-aco-reach-model-contract-by-cms https://www.windhamcap.com/news/upward-health-ranks-no-6-on-the-2024-inc-5000 https://www.windhamcap.com/news/upward-health-ranks-no-7-on-the-2023-inc-5000 https://www.windhamcap.com/news/valera-health-and-horizon-healthcare-services-collaborate-to-increase-access-to-mental-health-care-in-new-jersey https://www.windhamcap.com/news/valera-health-announces-45-million-growth-equity-financing-to-increase-access-to-evidence-based-mental-health-services-for-high-acuity-patients https://www.windhamcap.com/news/valera-health-expands-access-to-evidence-based-mental-health-care-including-suicide-prevention-services-with-acquisition-of-vita-health https://www.windhamcap.com/news/valera-health-secures-15m-led-by-windham-venture-partners-to-expand-the-companys-mental-health-clinical-services-across-the-u-s https://www.windhamcap.com/news/vergent-bioscience-awarded-national-cancer-institute-phase-2-grant-to-advance-clinical-development-of-vgt-309-in-lung-cancer https://www.windhamcap.com/news/vergent-bioscience-initiates-phase-2-multi-center-visualize-study-evaluating-efficacy-of-tumor-targeted-fluorescent-imaging-agent-vgt-309-in-lung-cancer-surgeries https://www.windhamcap.com/news/vergent-bioscience-presents-phase-2-data-showing-vgt-309-visualizes-tumors-in-the-lung-during-surgery https://www.windhamcap.com/news/vergent-bioscience-presents-phase-2b-visualize-results-demonstrating-abenacianine-for-injection-vgt-309-with-intraoperative-molecular-imaging-improved-tumor-visualization-during-lung-surgery https://www.windhamcap.com/news/vergent-bioscience-receives-fda-fast-track-designation-for-abenacianine-for-injection-vgt-309-to-help-surgeons-visualize-tumors-in-the-lung-during-surgery https://www.windhamcap.com/news/vergent-bioscience-secures-21-5-million-series-b-financing-to-advance-clinical-development-of-tumor-targeted-fluorescent-imaging-agent-vgt-309 https://www.windhamcap.com/news/waud-capital-partners-acquires-science-exchange-to-fuel-innovation-in-life-sciences-supplier-orchestration-technology https://www.windhamcap.com/news/why-vcs-are-investing-in-value-based-care https://www.windhamcap.com/news/willow-r-expands-product-suite-and-unveils-willow-go-tm-its-fully-in-bra-wearable-breast-pump-for-only-329 https://www.windhamcap.com/news/windham-capital-partners-appoints-former-new-york-medicaid-director-jason-helgerson-and-chief-digital-officer-and-chief-information-officer-of-emory-university-dr-alistair-erskine-as-venture-partners https://www.windhamcap.com/news/windham-venture-partners-hires-successful-healthcare-investor-david-kereiakes-and-expands-presence-in-the-midwest https://www.windhamcap.com/news/windrose-health-investors-completes-majority-growth-investment-in-subjectwell